Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil
Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopeni...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/10/21/5107 |
| _version_ | 1797512306564792320 |
|---|---|
| author | Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar |
| author_facet | Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar |
| author_sort | Mateusz Malik |
| collection | DOAJ |
| description | Sarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on the skeletal muscle area (SMA) at the level of the third lumbar vertebra. Progression-free survival (PFS) and overall survival (OS) were calculated from the treatment start. Neither initial sarcopenia nor ≥5% skeletal mass loss (SML) between CT1 and CT2 had a significant effect on PFS in treated patients (<i>p</i> = 0.5526 and <i>p</i> = 0.1092, respectively). In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11–3.72), <i>p</i> = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response. |
| first_indexed | 2024-03-10T05:58:58Z |
| format | Article |
| id | doaj.art-a4d0d1c41af74f5a98c83cefe33c0f6c |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T05:58:58Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-a4d0d1c41af74f5a98c83cefe33c0f6c2023-11-22T21:07:25ZengMDPI AGJournal of Clinical Medicine2077-03832021-10-011021510710.3390/jcm10215107Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/TipiracilMateusz Malik0Maciej Michalak1Barbara Radecka2Marek Gełej3Aleksandra Jackowska4Emilia Filipczyk-Cisarż5Katarzyna Hetman6Małgorzata Foszczyńska-Kłoda7Beata Kania-Zembaczyńska8Danuta Mańka9Marlena Orlikowska10Hanna Rogowska-Droś11Lubomir Bodnar12Lower Silesian Oncology Centre, Clinical Oncology Department, Plac Ludwika Hirszfelda 12, 53-413 Wroclaw, PolandDepartment of Radiology, Faculty of Medicine, University of Warmia and Mazury in Olsztyn, Aleja Warszawska 30, 11-082 Olsztyn, PolandDepartment of Oncology, Institute of Medical Sciences, University of Opole, Oleska 48, 45-052 Opole, PolandDepartment of Oncology, Institute of Medical Sciences, University of Opole, Oleska 48, 45-052 Opole, PolandOncology and Immunooncology Clinic, MSWiA Hospital, Warmia and Mazury Oncology Centre, Aleja Wojska Polskiego 37, 10-228 Olsztyn, PolandLower Silesian Oncology Centre, Clinical Oncology Department, Plac Ludwika Hirszfelda 12, 53-413 Wroclaw, PolandWest Pomeranian Oncology Center in Szczecin, Department of Clinical Oncology, Strzalowska 22, 71-730 Szczecin, PolandWest Pomeranian Oncology Center in Szczecin, Department of Clinical Oncology, Strzalowska 22, 71-730 Szczecin, PolandBeskid Oncology Centre in Bielsko-Biala, Department of Oncology and Oncohematology, Wyzwolenia 18, 43-300 Bielsko-Biala, PolandBeskid Oncology Centre in Bielsko-Biala, Department of Oncology and Oncohematology, Wyzwolenia 18, 43-300 Bielsko-Biala, PolandKociewie Health Centre, Oncology Department, Doktora Jozefa Balewskiego 1, 83-200 Starogard Gdanski, PolandDiagnostic Imaging Department, MSWiA Hospital, Warmia and Mazury Oncology Centre, Aleja Wojska Polskiego 37, 10-228 Olsztyn, PolandOncology and Immunooncology Clinic, MSWiA Hospital, Warmia and Mazury Oncology Centre, Aleja Wojska Polskiego 37, 10-228 Olsztyn, PolandSarcopenia is common in metastatic colorectal cancer (mCRC), increases the risk of treatment-related toxicity and reduces survival. Trifluridine/tipiracil (TT) chemotherapy significantly improved survival in refractory mCRC patients, but the prognostic and predictive role of pretherapeutic sarcopenia and variation in the skeletal muscle index (SMI) during this treatment has not been investigated so far. In this retrospective, observational study, clinical data on mCRC patients treated with TT at six cancer centres in Poland were collected. Computed tomography (CT) scans acquired at the time of initiation of TT (CT1) and on the first restaging (CT2), were evaluated. SMI was assessed based on the skeletal muscle area (SMA) at the level of the third lumbar vertebra. Progression-free survival (PFS) and overall survival (OS) were calculated from the treatment start. Neither initial sarcopenia nor ≥5% skeletal mass loss (SML) between CT1 and CT2 had a significant effect on PFS in treated patients (<i>p</i> = 0.5526 and <i>p</i> = 0.1092, respectively). In the multivariate analysis, reduced OS was found in patients with ≥5% SML (HR: 2.03 (1.11–3.72), <i>p</i> = 0.0039). We describe the prognostic role of sarcopenia beyond second line treatment and analyze other factors, such as performance status, tumor histological differentiation or carcinoembryonic antigen level that could predict TT treatment response.https://www.mdpi.com/2077-0383/10/21/5107sarcopeniametastatic colorectal cancercancer cachexiatrifluridine/tipiracil |
| spellingShingle | Mateusz Malik Maciej Michalak Barbara Radecka Marek Gełej Aleksandra Jackowska Emilia Filipczyk-Cisarż Katarzyna Hetman Małgorzata Foszczyńska-Kłoda Beata Kania-Zembaczyńska Danuta Mańka Marlena Orlikowska Hanna Rogowska-Droś Lubomir Bodnar Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil Journal of Clinical Medicine sarcopenia metastatic colorectal cancer cancer cachexia trifluridine/tipiracil |
| title | Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_full | Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_fullStr | Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_full_unstemmed | Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_short | Prognostic Value of Sarcopenia in Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil |
| title_sort | prognostic value of sarcopenia in metastatic colorectal cancer patients treated with trifluridine tipiracil |
| topic | sarcopenia metastatic colorectal cancer cancer cachexia trifluridine/tipiracil |
| url | https://www.mdpi.com/2077-0383/10/21/5107 |
| work_keys_str_mv | AT mateuszmalik prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT maciejmichalak prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT barbararadecka prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT marekgełej prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT aleksandrajackowska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT emiliafilipczykcisarz prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT katarzynahetman prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT małgorzatafoszczynskakłoda prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT beatakaniazembaczynska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT danutamanka prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT marlenaorlikowska prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT hannarogowskadros prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil AT lubomirbodnar prognosticvalueofsarcopeniainmetastaticcolorectalcancerpatientstreatedwithtrifluridinetipiracil |